Categorical Course

Interventional Oncology

200 (intermediate)

Advancing Interventional Oncology: Trials in Progress

Coordinator(s)

• 

  Kirema Garcia-Reyes, MD

  Assistant Professor
  Mount Sinai, United States
• VK

  Venkatesh Krishnasamy, MD (he/him/his)

  Associate Professor
  University of Alabama at Birmingham, United States

Interventional Oncology is in the midst of rapid evolution, with multiple phase II/III clinical trials poised to define the role of IR therapies across tumor types. This session will highlight active and upcoming IO trials, organized by disease focus—including liver, lung, renal, metastases, and emerging or competitive spaces. Faculty will synthesize the major studies within their area, providing attendees with a clear roadmap of the current IO research landscape and insight into the pivotal results expected to shape practice in the near future.

Presentations:

• 8:30 AM - 8:40 AM ET

  Redefining HCC: Ongoing Trials and Combination Strategies
  

  Speaker: Venkatesh P. Krishnasamy, MD (he/him/his) – University of Alabama at Birmingham
• 8:40 AM - 8:50 AM ET

  Locoregional and Systemic Integration for Liver Metastases: Trials in Progress
  

  Speaker: Zachary Berman, MD – University of California, San Diego
• 8:50 AM - 9:00 AM ET

  Trials and Emerging Data in Lung Cancer Ablation and IO
  

  Speaker: Robert Suh, MD – David Geffen School of Medicine at UCLA
• 9:00 AM - 9:10 AM ET

  Expanding the Role of IR in Renal Tumors: Ongoing Trials and Emerging Data
  

  Speaker: Andrew Gunn, MD – University of Kentucky
• 9:10 AM - 9:20 AM ET

  Emerging Frontiers: Trials in Pancreatic and Melanoma Interventions
  

  Speaker: Nadine Abi-Jaoudeh, MD, FSIR (she/her/hers) – University of California
• 9:20 AM - 9:30 AM ET

  Musculoskeletal Oncology: Emerging Trials in Bone and Soft Tissue Interventions
  

  Co-Speaker: Gina Landinez, MD (she/her/hers) – Miami Cardiac and Vascular Institute (MCVI) Miami Cancer Institute (MCI)
• 9:30 AM - 9:45 AM ET

  Q&A